Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This drug is a combination of the local anesthetic bupivacaine, the alpha-2 adrenergic agonist dexmedetomidine, and the vasoconstrictor epinephrine. It is used as a regional anesthetic mixture for field blocks to manage postoperative pain, specifically studied by Mansoura University in pediatric patients undergoing inguinal hernia surgery. Bupivacaine provides regional anesthesia by blocking sodium channels, dexmedetomidine acts as an analgesic adjunct to prolong the duration of the block and improve pain scores, and epinephrine acts as a vasoconstrictor to reduce systemic absorption and further extend the local effect.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bupivacaine + dexmedetomidine + epinephrine.